Structural Requirements of Maxadilan, a Non-Mammalian Potent Vasodilatory Peptide, for Interaction with the PAC-1 Receptor from Rat Brain Using a Synthetic Mini-Library

    loading  Checking for direct PDF access through Ovid

Abstract

Although there is no amino acid sequence similarity between maxadilan (Maxa) and pituitary adenylate cyclase activating polypeptide (PACAP), our synthetic Maxa was found to bind PACAP specific receptors (PAC-1 receptors) with a high affinity, but low potency for the accumulation of cAMP in PC12 cells. Competitive binding studies of 125I-PACAP-27 to rat cortical membranes allowed exploration of the structural requirements for this interaction using mini-libraries constructed by solid-phase peptided synthesis, that include disulfide isomers, N-, C- and middle segment deleted peptides and analogs. Maxa as well as PACAP38 inhibited the specific binding of 125I-PACAP-27 with IC50 values of 3.89 and 4.90 nM, respectively. The most potent derivative of our synthetic Maxa-analogs with an IC50 value of 1.99 nM was Maxa[1–23 + 43–61, S-S14–51 Ala1,5] which consists of N- (position 1–23) and C- (position 43–61) terminal linear fragments cross-linked by a disulfide bridge between positions 14 and 51. This peptide did not increase intracellular cAMP, at a concentration of 100 nM, but inhibited cAMP accumulation induced by 1 nM PACAP-27 in PC12 cells, whereas wild Maxa increased intracellular cAMP although it was weaker than PACAP-27. Our data suggest deletion of the middle segment between residues 24–42 affords some derivatives that behave as low affinity antagonists.

Related Topics

    loading  Loading Related Articles